Sage considers how to cut costs after FDA rejection; why drugs alone can't win the war against TB

Taking stock of the drug industry, from the lab to the medicine chest

August 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Drew Angerer/Getty Images STAT+ | Sage considers ways to reduce costs following FDA rejection on drug for major depression The agency granted clearance for the Sage drug, called Zurzuvae, to treat postpartum depression, but not major depression. By Brittany Trang Opinion: I saw firsthand in Nigeria that drugs alone can't win the war against tuberculosis I spent a year working with tuberculosis patients in Nigeria. There, I learned that access to medication is not enough. By Abdullahi Tsanni Kidney doctors push to protect patients by including dialysis machines in emergency stockpile Dialysis patients have a significantly higher risk of death in the 30 days following a hurricane compared to non-storm periods. By Carrie Arnold Andrew Harnik/AP STAT+ | FDA approves Sage Therapeutics' rapid-acting medication for postpartum depression but not major depression The agency denied Sage's application for an indication for major depression, a much larger potential market. By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser